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Stättermayer *et al*.[1](#apt12615-bib-0001){ref-type="ref"} reported on the accuracy of the recently discovered interferon‐*λ*4 (*IFNL4*) ss469415590 variant (TT or ΔG) in conjunction with the two widely studied interleukin 28B (*IL28B*) single‐nucleotide polymorphisms (SNPs), rs12979860 and rs8099917, for predicting the likelihood of a response to pegylated IFN‐α‐2a (PEG) and ribavirin (RBV) in a large set (n.754) of chronic hepatitis C virus (HCV) patients.

While *IFNL4* variant was strongly associated with a sustained virological response in both HCV genotypes 1 and 4, and thus confirmed previous findings by Prokunina‐Olsson *et al*.[2](#apt12615-bib-0002){ref-type="ref"} and Bibert *et al.,* [3](#apt12615-bib-0003){ref-type="ref"} the study confirms a strong linkage between ss469415590 and rs12979860 variants (ρ = 0.988) compared with the modest correlation between rs8099917 and *IFNL4* (ρ = 0.598). These findings therefore do not support an additional clinical benefit of *IFNL4* in the prediction of a response to PEG/RBV in Caucasian patients.

Recently, the finding that recombinant IFNL4 protein exerts a potent antiviral activity against both HCV and human coronaviruses[4](#apt12615-bib-0004){ref-type="ref"} works against the assumption that the same protein does inhibit clearance of HCV, i.e. negatively interfering with HCV infection, while being endowed with a strong anti‐HCV activity. This suggests the existence of a complex relationship between IFNL4 and HCV in humans, similar to that recently described for IFN‐1 and lymphocytic choriomeningitis virus in mice,[5](#apt12615-bib-0005){ref-type="ref"} where chronic IFN‐I signalling due to persistent infection drives immunosuppression and disease progression.

Although validation studies in large cohorts of patients, like the one investigated by Stättermayer *et al.,* [1](#apt12615-bib-0001){ref-type="ref"} may help understand the clinical utility of IFNL4, these studies have so far failed to demonstrate any causal relationship between IFNL4 protein and nonresponse to interferon therapy in chronic HCV patients. Among other approaches, the assessment of the missense variants previously described in the *IFNL4* coding region,[2](#apt12615-bib-0002){ref-type="ref"} may help unravel this issue.
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